Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Biological and molecular characterization of a canine hemangiosarcoma-derived cell line.

Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG.

Res Vet Sci. 2006 Aug;81(1):76-86. Epub 2005 Oct 25.

PMID:
16256156
2.

Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.

Thamm DH, Kurzman ID, King I, Li Z, Sznol M, Dubielzig RR, Vail DM, MacEwen EG.

Clin Cancer Res. 2005 Jul 1;11(13):4827-34.

3.

Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma.

Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, Vail DM.

Cancer Immunol Immunother. 2006 Apr;55(4):433-42. Epub 2005 Jun 18.

PMID:
15965647
4.

IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma.

MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, Wilson M, Radinsky R.

J Cell Biochem. 2004 May 1;92(1):77-91.

PMID:
15095405
5.

c-Met tyrosine kinase receptor expression and function in human and canine osteosarcoma cells.

MacEwen EG, Kutzke J, Carew J, Pastor J, Schmidt JA, Tsan R, Thamm DH, Radinsky R.

Clin Exp Metastasis. 2003;20(5):421-30.

PMID:
14524531
6.

In vitro effects of 2-methoxyestradiol on canine tumour cells.

Marr AK, Thamm DH, Kurzman ID, Vail DM, MacEwen EG.

Vet Comp Oncol. 2003 Sep;1(3):159-67. doi: 10.1111/j.1476-5829.2003.00022.x.

PMID:
19379315
7.

Intralesional lipid-complexed cytokine/superantigen immunogene therapy for spontaneous canine tumors.

Thamm DH, Kurzman ID, Macewen EG, Feinmehl R, Towell TL, Longhofer SL, Johnson CM, Geoly FJ, Stinchcomb DT.

Cancer Immunol Immunother. 2003 Aug;52(8):473-80. Epub 2003 May 27.

PMID:
12768328
8.

Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.

Thamm DH, MacEwen EG, Phillips BS, Hershey AE, Burgess KM, Pettit GR, Vail DM.

Cancer Chemother Pharmacol. 2002 Mar;49(3):251-5. Epub 2001 Dec 18.

PMID:
11935218
9.

Serum dehydroepiandrosterone sulfate concentrations across the life span of laboratory-housed rhesus monkeys.

Kemnitz JW, Roecker EB, Haffa AL, Pinheiro J, Kurzman I, Ramsey JJ, MacEwen EG.

J Med Primatol. 2000 Oct;29(5):330-7.

PMID:
11168823
10.

Spontaneously occurring tumors of companion animals as models for human cancer.

Vail DM, MacEwen EG.

Cancer Invest. 2000;18(8):781-92. Review.

PMID:
11107448
11.

Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: a pilot study.

Chun R, Kurzman ID, Couto CG, Klausner J, Henry C, MacEwen EG.

J Vet Intern Med. 2000 Sep-Oct;14(5):495-8.

12.

Use of cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II), a liposomal cisplatin analogue, in cats with oral squamous cell carcinoma.

Fox LE, Rosenthal RC, King RR, Levine PB, Vail DM, Helfand SC, MacEwen EG, Perez-Soler R, Calderwood-Mays M, Kurzman ID.

Am J Vet Res. 2000 Jul;61(7):791-5.

PMID:
10895902
13.

In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells.

Kurzman ID, Shi F, Vail DM, MacEwen EG.

Cancer Biother Radiopharm. 1999 Apr;14(2):121-8.

PMID:
10850295
14.

Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.

MacEwen EG, Kurzman ID, Vail DM, Dubielzig RR, Everlith K, Madewell BR, Rodriguez CO Jr, Phillips B, Zwahlen CH, Obradovich J, Rosenthal RC, Fox LE, Rosenberg M, Henry C, Fidel J.

Clin Cancer Res. 1999 Dec;5(12):4249-58.

15.

The immunotherapeutic potential of activated canine alveolar macrophages and antitumor monoclonal antibodies in metastatic canine melanoma.

Soergel SA, MacEwen EG, Vail DM, Potter DM, Sondel PM, Helfand SC.

J Immunother. 1999 Sep;22(5):443-53.

PMID:
10546161
16.

Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs.

Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Yang NS, MacEwen EG.

Cancer Gene Ther. 1999 Jan-Feb;6(1):26-36.

17.

Evaluation of toxicosis of liposome-encapsulated cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum (II) in clinically normal cats.

Fox LE, Toshach K, Calderwood-Mays M, Khokhar AR, Kubilis P, Perez-Soler R, MacEwen EG.

Am J Vet Res. 1999 Feb;60(2):257-63.

PMID:
10048562
18.

An accelerated technique for irradiation of malignant canine nasal and paranasal sinus tumors.

Adams WM, Miller PE, Vail DM, Forrest LJ, MacEwen EG.

Vet Radiol Ultrasound. 1998 Sep-Oct;39(5):475-81. Review.

PMID:
9771602
19.

Development of human granulocyte-macrophage colony-stimulating factor-transfected tumor cell vaccines for the treatment of spontaneous canine cancer.

Hogge GS, Burkholder JK, Culp J, Albertini MR, Dubielzig RR, Keller ET, Yang NS, MacEwen EG.

Hum Gene Ther. 1998 Sep 1;9(13):1851-61.

PMID:
9741424
20.
21.

Peripheral neuroblastoma in a dog.

Forrest LJ, Galbreath EJ, Dubielzig RR, MacEwen EG.

Vet Radiol Ultrasound. 1997 Nov-Dec;38(6):457-60.

PMID:
9402713
22.

Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.

Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG.

Cancer Chemother Pharmacol. 1997;39(5):410-6.

PMID:
9054954
23.
24.

In vivo particle-mediated cytokine gene transfer into canine oral mucosa and epidermis.

Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, Malter JS, MacEwen EG, Yang NS, Ershler WB.

Cancer Gene Ther. 1996 May-Jun;3(3):186-91.

PMID:
8725883
25.

Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993).

Bergman PJ, MacEwen EG, Kurzman ID, Henry CJ, Hammer AS, Knapp DW, Hale A, Kruth SA, Klein MK, Klausner J, Norris AM, McCaw D, Straw RC, Withrow SJ.

J Vet Intern Med. 1996 Mar-Apr;10(2):76-81.

26.

Canine osteosarcoma: amputation and chemoimmunotherapy.

MacEwen EG, Kurzman ID.

Vet Clin North Am Small Anim Pract. 1996 Jan;26(1):123-33. Review.

PMID:
8825571
27.

Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin.

Kurzman ID, MacEwen EG, Rosenthal RC, Fox LE, Keller ET, Helfand SC, Vail DM, Dubielzig RR, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Dec;1(12):1595-601.

28.

Response to liposome-encapsulated doxorubicin (TLC D-99) in a dog with myeloma.

Kisseberth WC, MacEwen EG, Helfand SC, Vail DM, London CL, Keller E.

J Vet Intern Med. 1995 Nov-Dec;9(6):425-8. No abstract available.

29.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial.

Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO Jr, et al.

Clin Cancer Res. 1995 Oct;1(10):1165-70.

30.

The effect of high fat diet and dehydroepiandrosterone (DHEA) administration in the rhesus monkey.

Christopher-Hennings J, Kurzman ID, Haffa AL, Kemnitz JW, Macewen EG.

In Vivo. 1995 Sep-Oct;9(5):415-20.

PMID:
8900917
31.
32.

Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma--a multicenter randomized double-blind study.

Fox LE, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Vail DM, Kisseberth W, London C, Madewell BR, Rodriguez CO Jr.

Cancer Biother. 1995 Summer;10(2):125-30. Erratum in: Cancer Biother 1995 Fall;10(3):249.

PMID:
7663571
33.

Prognostic factors for treatment of malignant lymphoma in dogs.

Teske E, van Heerde P, Rutteman GR, Kurzman ID, Moore PF, MacEwen EG.

J Am Vet Med Assoc. 1994 Dec 15;205(12):1722-8.

PMID:
7744644
34.

Hypocholesterolemic effect of exogenous dehydroepiandrosterone administration in the rhesus monkey.

Haffa AL, MacEwen EG, Kurzman ID, Kemnitz JW.

In Vivo. 1994 Nov-Dec;8(6):993-7.

PMID:
7772752
35.
36.

Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review.

MacEwen EG, Kurzman ID, Helfand S, Vail D, London C, Kisseberth W, Rosenthal RC, Fox LE, Keller ET, Obradovich J, et al.

J Drug Target. 1994;2(5):391-6.

PMID:
7704483
37.
38.
39.

Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma.

Keller ET, MacEwen EG, Rosenthal RC, Helfand SC, Fox LE.

J Vet Intern Med. 1993 Sep-Oct;7(5):289-95.

40.
41.

Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Vail DM, Elfarra AA, Cooley AJ, Panciera DL, MacEwen EG, Soergel SA.

Cancer Chemother Pharmacol. 1993;33(1):25-30.

PMID:
8269585
42.

Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells.

Smith BW, Kurzman ID, Schultz KT, Czuprynski CJ, MacEwen EG.

Cancer Biother. 1993 Summer;8(2):137-44.

PMID:
7804354
43.

Idiopathic granulomatous disease with ocular adnexal and cutaneous involvement in a dog.

Collins BK, MacEwen EG, Dubielzig RR, Swanson JF.

J Am Vet Med Assoc. 1992 Jul 15;201(2):313-6.

PMID:
1500332
44.
45.

Effect of colony-stimulating factors on number and function of circulating monocytes in normal dogs.

Kurzman ID, MacEwen EG, Broderick C, Witte P.

Mol Biother. 1992 Mar;4(1):29-33.

PMID:
1378283
46.

Obesity in the dog: role of the adrenal steroid dehydroepiandrosterone (DHEA).

MacEwen EG, Kurzman ID.

J Nutr. 1991 Nov;121(11 Suppl):S51-5. doi: 10.1093/jn/121.suppl_11.S51. Review.

PMID:
1834816
47.

Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment.

MacEwen EG.

Cancer Metastasis Rev. 1990 Sep;9(2):125-36. Review.

PMID:
2253312
48.

Plasma histamine and gastrin concentrations in 17 dogs with mast cell tumors.

Fox LE, Rosenthal RC, Twedt DC, Dubielzig RR, MacEwen EG, Grauer GF.

J Vet Intern Med. 1990 Sep-Oct;4(5):242-6.

49.

Biologic response modifiers: the future of cancer therapy?

MacEwen EG.

Vet Clin North Am Small Anim Pract. 1990 Jul;20(4):1055-73. Review.

PMID:
2196730
50.

Treatment of lymphoma in dogs.

Rosenthal RC, MacEwen EG.

J Am Vet Med Assoc. 1990 Mar 1;196(5):774-81. Review. No abstract available.

PMID:
2407706

Supplemental Content

Loading ...
Support Center